Lexaria Bioscience Corp. LEXX Archives - Page 37 of 39

WednesdaySep 01, 2021 11:11 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets with Drug Delivery Technology

Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective The company also released partial results from a human clinical study evaluating DehydraTECH-processed CBD for potential application against hypertension, which evidenced a rapid and sustained drop in blood pressure Growing hypertension and antiviral therapeutics market represent a potential win for Lexaria In July, Lexaria Bioscience (NASDAQ: LEXX), a drug delivery technology…

FridayAug 27, 2021 1:02 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery

Lexaria Bioscience Corp. (NASDAQ: LEXX) on July 22 announced it had met three primary objectives in its investigation of antiviral drug conversion process outcomes as the drugs are processed with its patented DehydraTECH(TM). “The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVID-19, HIV/AIDS, or other infectious disease-causing viruses, according to the company. The ultimate aim is to form partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics,” reads a recent…

TuesdayAug 24, 2021 10:29 am

Podcast Notes Blood Pressure Drug Delivery Trial Successes of Innovative Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology

Lexaria Bioscience is a drug delivery technology innovator whose flagship technology, DehydraTECH(TM), provides a means of enhancing substances’ delivery time to increase their effectiveness without adverse effects A new podcast by NetworkNewsAudio highlights DehydraTECH’s successes in trials that measure blood pressure reduction using DehydraTECH-enhanced CBD in comparison with generic controls The DehydraTECH technology is also being analyzed for effectiveness in combatting inflammatory conditions, viral illnesses and alternatives to the lung-harming effects of smoking The company’s most recent filing with the SEC notes that its revenues more than doubled between May 2020 and May 2021, driven largely by product sales and…

WednesdayAug 18, 2021 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented Technology Increasing Effectiveness and Potentially Lowering Healthcare Costs

Company’s patented DehydraTECH(TM) technology is showing the potential of reducing healthcare costs by improving oral medication administration – using capsule and pill form over injection administration Lexaria’s offering could potentially offer accelerated regulatory filing with the FDA and other regulators around the world The company sub-licenses its DehydraTECH technology for the delivery of fat-soluble active molecules and drugs while also operating four subsidiary companies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, recently announced results from an anti-viral drug molecular characterization study performed by the National Research Council (“NRC”). Results confirmed that the drugs tested remained stable and…

TuesdayAug 17, 2021 10:59 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in PCG Report Noting Company Could Deliver for Investors

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is featured in a report issued by PCG Digital Holdings LLC, an affiliate of PCG Advisory Inc. In the report, PCG noted that “Lexaria, delivering active ingredients to patients, could deliver for investors too.” The report stated that LEXX may be poised for a surge as the company’s DehydraTECH(TM) platform has proven to be an effective way to deliver active ingredients. The release noted that DehydraTECH had shown effectiveness as a hypertension treatment using CBD as well as with various antivirals. In addition, the release reported that DehydraTECH-enabled products are…

FridayAug 13, 2021 2:48 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Provides Potential for Significant Cost Savings to Health Care System

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the results of its antiviral drug molecular characterization study performed by the National Research Council (“NRC”). The results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with DehydraTECH. “This could preserve the ability of this drug delivery platform to qualify for accelerated regulatory filings with the Food and Drug Administration (‘FDA’) in the United States plus regulators elsewhere in the world,” reads a recent article. “The potential for more rapid market authorization of DehydraTECH provides the potential for cost savings to the health care…

WednesdayAug 11, 2021 12:38 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Partial Results from Human Clinical Trial of DehydraTECH(TM)-Processed Cannabidiol for Hypertension

Clinical study HYPER-H21-1 evaluates the use of patented DehydraTECH(TM)-processed CBD for use against hypertension Hypertension is a primary or contributing factor in the death of almost 500,000 people per year, with approximately one in four adults aged 20 to 44 suffering from high blood pressure Initial results of the study show that blood pressure was reduced in both male and female volunteers, resulting in the reinforcement of pre-existing findings demonstrating that DehydraTECH delivers superior performance Lexaria plans on launching two additional clinical trials, for a total of three clinical trials in 2021 for the DehydraTECH-CBD with hypertension applications Lexaria (NASDAQ:…

FridayAug 06, 2021 1:58 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals

Lexaria Bioscience Corp. (NASDAQ: LEXX) is constantly collaborating with research institutions and businesses to identify new ways to innovate and improve its DehydraTECH(TM) drug-delivery technology. DehydraTECH is already being monetized through commercial use, and the company is utilizing advanced 2.0 formulations in ongoing human studies. A recent article discusses Lexaria’s move to consolidate the trading of its shares solely on the Nasdaq, and resulting advantages to the company and its shareholders. “Since it was listed back in January 2021, a substantial fraction of its shareholders moved onto this exchange. To them, it offered more liquidity than ever before, and to…

FridayAug 06, 2021 9:30 am

First Results from Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Show Marked Gains in Blood Pressure Reduction over Generic CBD Controls

Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls The complete results of the study will be produced as sample and data analyses work are completed Lexaria is…

MondayAug 02, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives

Lexaria just completed dosing for its second human clinical study, HYPER-H21-2 The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX